New update: Luspatercept-aamt (REBLOZYL®) is a preferred, first-line treatment option for symptomatic anemia in RS- and RS+ LR-MDS as recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1*
REBLOZYL FOR PATIENTS WITH ANEMIA DUE TO MDS or beta-thalassemia
REBLOZYL: the only FDA approved first-line treatment for patients with MDS associated anemia2
Explore results from the only head-to-head study vs an ESA in anemia due to LR-MDS2,3
*For patients with IPSS-R very low-, low-, or intermediate-risk MDS with non-del(5q) ± other cytogenetic abnormalities and with RS <15% (or RS <5% with SF3B1 mutation) with sEPO ≤500 mU/mL or with non-del(5q) ± other cytogenetic abnormalities with RS ≥15% (or RS ≥5% with an SF3B1 mutation).1
Learn more about how REBLOZYL can help patients with anemia due to MDS or beta-thalassemia
The COMMANDS study compared REBLOZYL vs epoetin alfa. The primary endpoint was RBC transfusion independence for ≥12 weeks along with a mean improvement in Hgb by ≥1.5 g/dL during Weeks 1 to 24.2
In the MEDALIST study, the primary endpoint was RBC transfusion independence ≥8 weeks during Weeks 1 to 24.2
In the BELIEVE study, the primary endpoint was ≥33% reduction in RBC transfusion burden of at least 2 units from Weeks 13 to 24.2
ESA=erythropoiesis-stimulating agent; Hgb=hemoglobin; IPSS-R=Revised International Prognostic Scoring System; LR-MDS=lower-risk myelodysplastic syndromes; MDS=myelodysplastic syndromes; MDS-RS=myelodysplastic syndromes with ring sideroblasts; NCCN=National Comprehensive Cancer Network; RBC=red blood cell; RS=ring sideroblast; sEPO=serum erythropoietin.
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.1.2025. National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 18, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2024. 3. Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10399):373-385.
